FDA hands down ap­proval for Bris­tol My­er­s' lung can­cer drug from Turn­ing Point buy­out

Bris­tol My­ers Squibb’s $4.1 bil­lion buy­out of Turn­ing Point Ther­a­peu­tics has paid off, with the FDA hand­ing down an ap­proval of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.